Related Experiment Video
Updated: Feb 16, 2026

07:12
Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
Published on: August 2, 2021
4.3K
Aperture effect for LINAC-based SRS in small target treatment†
Kaile Li1,2
1John R Marsh Cancer Center, Hagerstown, MD 21742, USA.
Journal of Radiosurgery and SBRT
|January 4, 2018
Summary
For small target Stereotactic Radiosurgery (SRS), Multi-Leaf Collimator (MLC) plans show greater variability in dose distribution and conformity than cone-based plans. This comparison aids treatment selection for small cranial targets.
Area of Science:
- Medical Physics
- Radiation Oncology
- Radiosurgery Techniques
Background:
- Stereotactic Radiosurgery (SRS) employs various techniques for precise radiation delivery.
- The choice of aperture (cone or Multi-Leaf Collimator/MLC) significantly impacts treatment for small targets in SRS.
- Understanding dosimetric differences between MLC and cone techniques is crucial for optimizing small target SRS.
Purpose of the Study:
- To compare the dosimetric characteristics of cone-based and MLC-based techniques for Stereotactic Radiosurgery (SRS) of small cranial targets.
- To evaluate how varying aperture sizes influence dose distribution and conformity in small target SRS.
Main Methods:
- Utilized an anthropomorphic phantom with a 4mm spherical cranial target.
- Generated single 360 ARC plans using Varian Eclipse system for both cone and MLC techniques.
- Compared plans based on varying aperture sizes (MLC margins: 2-6mm; cone diameters: 5-16mm).
- Assessed dosimetric parameters including 12Gy Volume (V12Gy), Max Dose to Prescription Dose ratio (MDPD), Prescription Isodose Volume to Target Volume ratio (PITV), and conformity indices (RCI, ICI).
Main Results:
- MLC plans exhibited larger variations in V12Gy (1.0-5.3cc) and PITV (average 0.80) compared to cone plans (V12Gy: 0.1-3.2cc, PITV average 0.54).
- Integrated Conformity Index (ICI) showed higher variability (up to 45%) with MLC plans compared to cone plans (7%).
- Maximum Dose to Prescription Dose (MDPD) variations were comparable between MLC (9%) and cone (12%) plans.
Conclusions:
- MLC-based SRS plans for small targets demonstrate greater variability in V12Gy, PITV, and ICI than cone-based plans.
- MDPD differences were not significant between the two techniques at the selected aperture sizes.
- Findings can inform treatment planning decisions for small target SRS, pending further clinical outcome data and investigation into advanced planning algorithms.
More Related Videos
Related Concept Videos
Open Angle Glaucoma: Treatment
1.0K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.0K
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Parkinson's Disease: Treatment
1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Alzheimer's Disease: Treatment
987
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
987
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Anticholinesterase Agents: Poisoning and Treatment
1.7K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.7K

